Klaus Olgaard

List of Publications by Year
in descending order

75 papers	3,023 citations	201674 27 h-index	168389 53 g-index
77 all docs	77 docs citations	77 times ranked	3125 citing authors

#	Article	IF	Citations
1	The Calcified Vasculature in Chronic Kidney Disease Secretes Factors that Inhibit Bone Mineralization. JBMR Plus, 2022, 6, e10610.	2.7	3
2	Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney International, 2022, 101, 1232-1250.	5.2	8
3	Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets. Frontiers in Immunology, 2021, 12, 684015.	4.8	8
4	Effect of NAD+ boosting on kidney ischemia-reperfusion injury. PLoS ONE, 2021, 16, e0252554.	2.5	19
5	The Vascular Circadian Clock in Chronic Kidney Disease. Cells, 2021, 10, 1769.	4.1	5
6	Diurnal variation of magnesium and the mineral metabolism in patients with chronic kidney disease. Bone Reports, 2021, 15, 101130.	0.4	7
7	New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Diseaseâ€“Mineral and Bone Disorder. Metabolites, 2021, 11, 849.	2.9	8
8	New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis. International Journal of Molecular Sciences, 2020, 21, 8810.	4.1	35
9	A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. Kidney International, 2020, 98, 1461-1475.	5.2	20
10	Circadian rhythms of mineral metabolism in chronic kidney diseaseâ€“mineral bone disorder. Current Opinion in Nephrology and Hypertension, 2020, 29, 367-377.	2.0	17
11	Chronic Kidney Diseaseâ€“Induced Vascular Calcification Impairs Bone Metabolism. Journal of Bone and Mineral Research, 2020, 36, 510-522.	2.8	24
12	Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats. Pflugers Archiv European Journal of Physiology, 2019, 471, 1079-1094.	2.8	22
13	Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. American Journal of Physiology - Renal Physiology, 2018, 314, F753-F762.	2.7	26
14	Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. Calcified Tissue International, 2018, 102, 85-92.	3.1	29
15	Effect of inhibition of CBP-coactivated Î²-catenin-mediated Wnt signalling in uremic rats with vascular calcifications. PLoS ONE, 2018, 13, e0201936.	2.5	11
16	Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. PLoS ONE, 2018, 13, e0190820.	2.5	17
17	Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney International, 2017, 92, 165-178.	5.2	42
18	Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. American Journal of Physiology - Renal Physiology, 2016, 310, F477-F491.	2.7	45

#	Article	IF	Citations
19	The vascular secret of Klotho. Kidney International, 2015, 87, 1089-1091.	5.2	24
20	Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney International, 2015, 88, 1304-1313.	5.2	57
21	A potential kidney - bone axis involved in the rapid minute-to-minute regulation of plasma Ca2+. BMC Nephrology, 2015, 16, 29.	1.8	17
22	Parathyroid hormone-related peptide plasma concentrations in patients on hemodialysis. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 206-212.	1.2	6
23	Circulating FGF23 Levels in Response to Acute Changes in Plasma Ca2+. Calcified Tissue International, 2014, 95, 46-53.	3.1	16
24	High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrology, 2013, 14, 281.	1.8	25
25	Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4â€“5. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 107-116.	1.2	25
26	Epigenetic Methylation of ParathyroidCaRandVDRPromoters in Experimental Secondary Hyperparathyroidism. International Journal of Nephrology, 2012, 2012, 1-9.	1.3	10
27	The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney International, 2011, 79, 742-748.	5.2	15
28	Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nature Immunology, 2010, 11, 344-349.	14.5	493
29	Increased parathyroid expression of klotho in uremic rats. Kidney International, 2010, 78, 1119-1127.	5.2	63
30	Opinion: When is Vitamin D Contraindicated in Dialysis Patients?. Seminars in Dialysis, 2009, 22, 240-242.	1.3	2
31	A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis, 2008, 201, 274-280.	0.8	42
32	Reply to Dr S.C. Palmer and co-workers. Nephrology Dialysis Transplantation, 2008, 23, 2709-2710.	0.7	1
33	Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease [1] and an editorial comment [2] accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership. Nephrology Dialysis Transplantation, 2008, 23, 1786-1789.	0.7	12
34	Abnormal Bone and Mineral Metabolism in Kidney Transplant Patients â€“ A Review. American Journal of Nephrology, 2008, 28, 246-253.	3.1	71
35	Cardiac structure and function in a mouse model of uraemia without hypertension. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 660-666.	1.2	14
36	Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1080-1086.	2.4	28

#	Article	IF	Citations
37	Effect of 1,25-dihydroxy-vitamin D₃ in experimental sepsis. International Journal of Medical Sciences, 2007, 4, 190-195.	2.5	57
38	Basic Science and Dialysis: Parathyroid Growth and Suppression in Renal Failure. Seminars in Dialysis, 2006, 19, 238-245.	1.3	16
39	Klotho, an important new factor for the activity of Ca2+ channels, connecting calcium homeostasis, ageing and uraemia. Nephrology Dialysis Transplantation, 2006, 21, 1770-1772.	0.7	14
40	Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. Nephrology Dialysis Transplantation, 2006, 21, 1766-1769.	0.7	24
41	Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands. Journal of the American Society of Nephrology: JASN, 2006, 17, 1923-1930.	6.1	42
42	Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 570-575.	2.4	29
43	Can Hyperparathyroid Bone Disease Be Arrested or Reversed?. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 367-373.	4.5	9
44	Impaired kidney growth in low-birth-weight children: Distinct effects of maturity and weight for gestational age. Kidney International, 2005, 68, 731-740.	5.2	95
45	Comparison between 1Î±(OH)D₃ and 1,25(OH)₂D₃ on the Suppression of Plasma PTH Levels in Uremic Patients, Evaluated by the â€˜Wholeâ€™ and â€˜Intactâ€™ PTH Assays. Nephron Clinical Practice, 2005, 99, c128-c137.	2.3	4
46	Increased Expression of Adhesion Molecules in Uremic Atherosclerosis in Apolipoprotein-E-Deficient Mice. Journal of the American Society of Nephrology: JASN, 2004, 15, 1495-1503.	6.1	68
47	Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrology Dialysis Transplantation, 2004, 19, 870-876.	0.7	67
48	Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. American Journal of Kidney Diseases, 2004, 43, 558-565.	1.9	147
49	Kidney growth in 717 healthy children aged 0?18ï¿½months: a longitudinal cohort study. Pediatric Nephrology, 2004, 19, 992-1003.	1.7	47
50	Increased kidney growth in formula-fed versus breast-fed healthy infants. Pediatric Nephrology, 2004, 19, 1137-44.	1.7	43
51	Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney International, 2003, 64, 63-70.	5.2	21
52	Posttransplant bone disease. Transplantation Reviews, 2003, 17, 176-186.	2.9	19
53	Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein Eâ€“Deficient Mice. Journal of the American Society of Nephrology: JASN, 2003, 14, 2466-2474.	6.1	138
54	Pharmacokinetics of 1,25(OH)2D3 and 1alpha(OH)D3 in normal and uraemic men. Nephrology Dialysis Transplantation, 2002, 17, 829-842.	0.7	41

#	Article	IF	Citations
55	Persistent Downregulation of Calcium-Sensing Receptor mRNA in Rat Parathyroids when Severe Secondary Hyperparathyroidism Is Reversed by an Isogenic Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2002, 13, 2110-2116.	6.1	54
56	Separate Effects of 1,25-Dihydroxyvitamin D and Calcium on Renal Calbindin-D28k and Intestinal Calbindin-D9k. Basic and Clinical Pharmacology and Toxicology, 2002, 91, 111-115.	0.0	7
57	Prevention of Uremic Bone Disease Using Calcimimetic Compounds. Annual Review of Medicine, 2001, 52, 203-220.	12.2	20
58	PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. Kidney International, 2000, 58, 71-81.	5.2	26
59	Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney International, 1999, 56, 1084-1093.	5.2	270
60	1,25(OH)2D3 only affects long-term levels of plasma Ca2+ but not the rapid minute-to-minute plasma Ca2+ homeostasis in the rat. Steroids, 1999, 64, 726-734.	1.8	12
61	The Effect of 1,25â€Vitamin D₃ on Calbindinâ€Ð and Calciumâ€Metabolic Variables in the Rat. Basic and Clinical Pharmacology and Toxicology, 1998, 82, 118-121.	0.0	6
62	Effects of excess PTH on nonclassical target organs. American Journal of Kidney Diseases, 1997, 30, 606-620.	1.9	118
63	Reversibility of experimental secondary hyperparathyroidism. Kidney International, 1997, 52, 1232-1241.	5.2	43
64	A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrology Dialysis Transplantation, 1996, 11, 1762-1768.	0.7	59
65	Effect of parathyroid hormone on renal calbindin-D28k. Journal of Bone and Mineral Research, 1996, 11, 1086-1093.	2.8	20
66	The calcium/parathyroid hormone concept of the parathyroid glands. Current Opinion in Nephrology and Hypertension, 1995, 4, 324-333.	2.0	22
67	Calcium metabolic changes and calbindin-D in experimental hypertension. Journal of Hypertension, 1994, 12, 901???908.	0.5	6
68	Parathyroid hormone dependent T cell proliferation in uremic rats. Kidney International, 1993, 44, 379-384.	5.2	21
69	Metabolism of Prednisone in Kidney Transplanted Patients with Necrosis of the Femoral Head. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 78-83.	0.0	7
70	Steroid-induced mandibular bone loss in relation to marginal periodontal changes. Journal of Clinical Periodontology, 1992, 19, 182-186.	4.9	46
71	Influence of Calcium on the Metabolism of Intact Parathyroid Hormone by Isolated Perfused Rat Kidney and Liver*. Endocrinology, 1990, 126, 1813-1820.	2.8	19
72	Effect of Intravenous 1-Alpha-Hydroxyvitamin D₃ on Secondary Hyperparathyroidism in Chronic Uremic Patients on Maintenance Hemodialysis. Nephron, 1989, 53, 194-200.	1.8	24

#	Article	IF	Citations
73	Bone mineral content by photon absorptiometry of the mandible compared with that of the forearm and the lumbar spine. Calcified Tissue International, 1988, 42, 157-161.	3.1	68
74	Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia. Kidney International, 1984, 26, 791-797.	5.2	17
75	Lack of influence of 24,25-dihydroxyvitamin D3 on parathyroid hormone secretion from normal or hyperplastic glands. Calcified Tissue International, 1983, 35, 449-454.	3.1	4